Harrow (HROW) Competitors $45.47 -2.26 (-4.73%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, TGTX, and CRSPShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics CRISPR Therapeutics Harrow (NASDAQ:HROW) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Do insiders and institutionals have more ownership in HROW or GRFS? 72.8% of Harrow shares are held by institutional investors. 15.2% of Harrow shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is HROW or GRFS more profitable? Grifols has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Grifols' return on equity of 0.00% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.18% -0.35% Grifols N/A N/A N/A Which has preferable valuation & earnings, HROW or GRFS? Grifols has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M8.42-$17.48M-$0.25-181.66Grifols$7.81B0.88$169.80M$1.178.53 Do analysts rate HROW or GRFS? Harrow currently has a consensus price target of $68.50, suggesting a potential upside of 50.83%. Grifols has a consensus price target of $10.30, suggesting a potential upside of 3.15%. Given Harrow's stronger consensus rating and higher probable upside, equities research analysts plainly believe Harrow is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more risk & volatility, HROW or GRFS? Harrow has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Does the media favor HROW or GRFS? In the previous week, Harrow had 31 more articles in the media than Grifols. MarketBeat recorded 33 mentions for Harrow and 2 mentions for Grifols. Harrow's average media sentiment score of 0.58 beat Grifols' score of -0.50 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 7 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative SummaryGrifols beats Harrow on 9 of the 17 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68B$2.61B$6.10B$10.57BDividend YieldN/A56.45%5.68%4.67%P/E Ratio-181.6024.3677.7626.88Price / Sales8.42532.10521.66204.63Price / Cash353.73175.2237.8961.20Price / Book23.295.3512.546.58Net Income-$17.48M$32.92M$3.30B$277.11M7 Day Performance-3.58%4.06%28,071.68%2.86%1 Month Performance21.63%9.91%29,009.43%9.79%1 Year Performance-8.71%-2.11%35,796.25%33.02% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow3.0999 of 5 stars$45.42-4.9%$68.50+50.8%+4.0%$1.68B$199.61M-181.60180Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.1619 of 5 stars$9.93+1.1%$10.30+3.7%+13.3%$6.75B$7.81B8.4923,822Short Interest ↑RYTMRhythm Pharmaceuticals3.5299 of 5 stars$100.64+1.5%$106.64+6.0%+90.6%$6.59B$130.13M-33.44140RNAAvidity Biosciences2.495 of 5 stars$42.63-0.7%$68.32+60.3%-6.2%$6.27B$10.90M-11.97190Positive NewsABVXAbivax3.3602 of 5 stars$83.33+0.6%$102.14+22.6%+698.4%$6.26BN/A0.0061Analyst RevisionLEGNLegend Biotech2.9239 of 5 stars$32.85-1.6%$74.22+125.9%-33.7%$6.16B$627.24M-37.332,609CYTKCytokinetics3.992 of 5 stars$53.89+6.9%$75.71+40.5%+7.1%$6.03B$18.47M-10.57250Analyst ForecastInsider TradeNUVLNuvalent3.051 of 5 stars$84.84+4.2%$119.50+40.9%-19.0%$5.87BN/A-17.3140Insider TradeAXSMAxsome Therapeutics4.804 of 5 stars$117.62+0.7%$177.86+51.2%+28.6%$5.83B$385.69M-23.20380Trending NewsAnalyst ForecastAnalyst RevisionTGTXTG Therapeutics3.9631 of 5 stars$36.83+3.7%$48.00+30.3%+63.8%$5.63B$329M99.54290CRSPCRISPR Therapeutics1.6614 of 5 stars$63.77+3.4%$71.50+12.1%+59.3%$5.61B$37.31M-11.74460 Related Companies and Tools Related Companies Grifols Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Abivax Alternatives Legend Biotech Alternatives Cytokinetics Alternatives Nuvalent Alternatives Axsome Therapeutics Alternatives TG Therapeutics Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
